Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...

PIK3CA/PTEN遺伝子変異、DNA損傷応答（DDR）経路に異常を有する進行固形癌において、PI3K阻害薬copanlisibとオラパリブの併用療法は良好な忍容性と抗腫瘍活性を示したことが、フェーズ1b試験の結果から示された。4月5日から10日にサンディエゴで開催されたAmerican ...

Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...

PI3K経路の遺伝子に変異を有する大腸癌（CRC）患者において、低用量アスピリンの術後3年間投与は再発率を有意に低下させることが、ランダム化プラセボ対照ALASCCA試験の観察期間3年の結果で明らかになった。1月23日から25日に米サンフランシスコで開催され ...

We share the story of a pioneering and collaborative research programme at the ICR, initiated in the late 1990s, that led to one of the first clinical-stage PI3K inhibitors, laying the foundation for ...

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...